Preclinical-stage developer of engineered protein biologics that exploit cancer-specific vulnerabilities to eradicate tumors while prioritizing patient safety and reduced side effects. Targets common pediatric cancers and difficult-to-treat malignancies (acute myeloid leukemia, pancreatic, liver, ovarian) using known drug mechanisms plus genomic/epigenetic markers to select patients likely to benefit.